Fight for Your Chance for a Cure* with INCIVEK Triple Therapy
SOME GOOD NEWS: Chronic hepatitis C can be cured*
in many patients
Treatment options for hepatitis C have improved a great deal since the 1990s.
Today there are more approved treatments, including INCIVEK Triple Therapy.
INCIVEK Triple Therapy (pronounced in-SEE-veck) is a combination of 3 prescription medicines (INCIVEK + peginterferon alfa + ribavirin) used to treat chronic hepatitis C (genotype 1) infection in adults with stable liver problems, who have not been treated before or who have failed previous treatment.
The goal of INCIVEK Triple Therapy is to cure hepatitis C. Cure, or clearing the virus, means the hepatitis C virus is not detectable in your blood 6 months after you finish all treatment. This is also known as Sustained Virologic Response (SVR).
Approximately 65,000 people in the U.S. have been prescribed INCIVEK as part of INCIVEK Triple Therapy for a chance to cure their hepatitis C.†
With INCIVEK Triple Therapy:
- Better chance of a cure than with peginterferon alfa and ribavirin alone (even if you have been treated before for hepatitis C). Cure means you can’t detect the hepatitis C virus in your blood 6 months after you finish all treatment. Not everyone who undergoes INCIVEK Triple Therapy achieves cure. See how INCIVEK Triple Therapy worked in clinical trials
- Know early how and if your body is responding to treatment. Blood tests at weeks 4 and 12 can tell your healthcare provider more about your chances of being cured. If the treatment is not working, your healthcare provider will stop it
- Treatment is 24 or 48 weeks. And you only take INCIVEK for the first 12 weeks. Blood tests at weeks 4, 12, and 24 can tell your healthcare provider more about your chances of being cured
†Patient Regimens Monthly Report, IMS Health, NPA through October 2013.